Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OIG targets oxygen payments

This article was originally published in The Gray Sheet

Executive Summary

Report from the HHS Office of Inspector General Sept. 14 recommends CMS limit the rental period for home oxygen equipment to 13 months, as outlined in the President's budget for fiscal 2007, for Medicare and beneficiary savings of $3.2 bil. over five years. CMS believes that OIG's savings estimates may be inflated, but concurs that a 36-month cap on rewards mandated by the Deficit Reduction Act, enacted in February, does not go far enough to address overpayments (1"The Gray Sheet" Jan. 2, 2006, p. 12). According to OIG, over a 36-month rental, suppliers would receive payments of $7,215 for concentrators that cost on average $587. The Council for Quality Respiratory Care, whose members include Invacare and Sunrise Medical, challenges the findings and points to a 2006 study by Morrison Informatics showing that 72% of the cost of providing home oxygen therapy involves patient care and services, not equipment. A bill (S 3814) introduced in August would ensure that CMS continue renting oxygen equipment for beneficiaries as long as they require it (2"The Gray Sheet" Aug. 14, 2006, In Brief)...

You may also be interested in...

Invacare Rallies Ohio Republicans To Extend Medical Equipment Payments

Durable medical equipment (DME) maker Invacare successfully lobbied members of Congress to fight a last-minute Medicare budget provision that would have stopped rental payments to oxygen tank providers after 18 months of use

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts